UNSPSC 51383506: Pravadoline

This classification denotes a cyclooxygenase inhibitor with the molecular formula C23H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P3JW662TWA, chemically known as methanone, (4-methoxyphenyl)(2-methyl-1-(2-(4-morpholinyl)ethyl)-1h-indol-3-yl)- but generally known as pravadoline, which bears US NIH Compound Identifier 56463. European Medicines Agency schedules Pravadoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10003MIG.

UNSPSC 51383506 Pravadoline is a Commodity code that nominally identifies a specific pharmaceutical compound, but recent state and local procurement activity tagged under this code does not align with pravadoline itself. Instead, the opportunities solicited reflect a broader pharmaceutical and drug-management category spanning naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local issuers purchasing under this code span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The actual work being solicited includes procuring finished pharmaceutical products for community health initiatives and pharmacy benefit programs, establishing manufacturer relationships for prescription fulfillment, and acquiring drug deactivation and opioid-reversal systems for public health support. Issuing bodies include Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement.

Recent activity centers in Florida, Texas, and Minnesota. Representative opportunities include Seminole County's IFB60459723LAS, posted June 30, 2026, requesting 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: this date appears inconsistent with the posting date and reflects a source data anomaly); MMCAP's S1070000015802 RFP, posted January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities with a response deadline of March 26, 2026; and the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, soliciting vendor information on direct-to-manufacturer prescription programs. The MMCAP contract requires vendors to work through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification, while Seminole County's procurement emphasizes fixed-fee pricing and quarterly fulfillment logistics. The code shows sparse but geographically dispersed activity; the mismatch between the code's pharmaceutical-compound identity and the actual scope of purchased goods and services suggests potential classification drift in state and local procurement systems.